Dr Daniel Kantor Highlights MS Treatments and What Is in the Pipeline

Dr Daniel Kantor Highlights MS Treatments and What Is in the Pipeline
Sept 2019

The field of treatments for Multiple Sclerosis (MS) has grown quickly in the last 30 years, but the next new class of therapies probably won’t come to market for at least another year and a half, said Daniel Kantor, MD, president of Kantor Neurology.

kessler

Are there any particular Multiple Sclerosis trials that you’re keeping an eye on?

The field of MS is exciting. We’ve gone from having zero disease-modifying therapies in 1992, to our first medication in 1993, to, now, having 17 separate products. It’s amazing the leap forward. We now have 14 branded products, we have 2 unbranded generics, and 1 branded generic. That’s an amazing leap forward. That’s faster than anything in neurology, and frankly, faster than most things in medicine.

Click the above banner to listen to Dr. Kantor's response




........................................................................................................
This Article is Provided by:  #MSViewsandNews
::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::
Visit our MS Learning Channel on YouTube: http://www.youtube.com/msviewsandnews
kessler
(Originally posted by Stuart)
June Halper on How Supportive Team Care Can Help P...
Quiz Time: What's the Marriage-Mortality Connectio...
 

Comments

No comments made yet. Be the first to submit a comment
Already Registered? Login Here
Guest
Wednesday, 13 November 2019

 
 

Follow Us on Twitter

Follow Us On Twitter - Image